Compugen Ltd. (NASDAQ: CGEN)
announced today that pre-clinical findings presented at the 3rd
European Congress of Immunology provide additional support for the
potential of CGEN-15001 to effectively treat autoimmune disease. Mode of
action studies for CGEN-15001 demonstrated both the active suppression
of pathogenic immune responses and the reestablishment of immune balance
by increasing anti-inflammatory mediators and promoting inducible
regulatory T cells (iTregs). Modulation of iTregs is considered an
extremely promising approach for treatment of autoimmunity and cancer,
and therefore has been the focus of intense industry and academic
research in recent years.

These results were included in a presentation focused on CGEN-15001 by
Dr. Joseph R. Podojil, a